Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Topical everolimus 0.05% for adenoma sebaceum in tuberous sclerosis
TCTR20180820002Phase 2Recruiting
- Sponsor
- King Chulalongkorn Memorial Hospital
- Start
- Mar 2014
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of everolimus in facial angiofibroma, tuberous sclerosis complex (TSC), sponsored by King Chulalongkorn Memorial Hospital. Started Mar 2014; status: recruiting.
02
Drugs
everolimus
03
Conditions
facial angiofibromatuberous sclerosis complex (TSC)
Beyond the preview
Go deeper on TCTR20180820002.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on TCTR20180820002.